Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Somapacitan once weekly versus Norditropin once daily in children with short stature disorders
NL-OMON60312Phase 3Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Dec 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of somapacitan and somatropin in Short stature in children born small for gestational age, Turner syndrome (TS), Noonan syndrome and 1 more (2 arms), sponsored by Novo Nordisk. Primary endpoint: Height velocity. Started Dec 2022; status: active, not recruiting.
02
Drugs
somapacitansomatropin
03
Conditions
Short stature in children born small for gestational ageTurner syndrome (TS)Noonan syndromeIdiopathic Short Stature (ISS)
Beyond the preview
Go deeper on NL-OMON60312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60312.